FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947394857> ?p ?o ?g. }

• W2947394857 abstract "To validate the robust predictive values of tumor vascularity and hand-foot-skin reaction (HFSR) in combination treatment of transarterial chemoembolization (TACE) and sorafenib for patients with intermediate hepatocellular carcinoma (HCC), and then select the potential candidates who would survive best from such treatment.A total of 132 treatment-naive patients with intermediate HCC undergoing combination therapy of TACE and sorafenib were recruited between January 2010 and December 2014. The tumor vascularity was defined according to digital subtraction angiography (DSA) and HFSR was assessed by the national cancer institute common terminology criteria for adverse events (NCI-CTCAE). The Mann-Whitney U test was used to assess the correlation between vascularity and radiologic response; time to radiologic progression (TTP) and overall survival (OS) were evaluated using Kaplan-Meier techniques and compared by log-rank test; factors associated with them were evaluated using multivariate Cox regression analysis.During a median follow up of 17.3 months, it was revealed that hypervascularity and development of ≥2 grade of HFSR within 60 days after sorafenib initiation were favorable predictors for TTP (HR 0.378, p < 0.001; HR 0.627, p = 0.018) and OS (HR 0.499, p = 0.002; HR 0.555, p = 0.004). The median TTP and OS for patients with both were 12.2 and 29.1 months, which were better than patients with either of them (6.0 months, HR 1.74, p = 0.012; 16.5 months, HR 1.73, p = 0.021), as well as those with neither (2.9 months, HR 3.74, p < 0.001; 11.9 months, HR 3.17, p < 0.001).Tumor hypervascularity and development of ≥2 grade of HFSR within 60 days were favorable predictive factors for the combination treatment of TACE and sorafenib, with both of which the patients survived longest and might be the potential candidates." @default.
• W2947394857 created "2019-06-07" @default.
• W2947394857 creator A5002366018 @default.
• W2947394857 creator A5018694636 @default.
• W2947394857 creator A5023597320 @default.
• W2947394857 creator A5031254409 @default.
• W2947394857 creator A5036608985 @default.
• W2947394857 creator A5059500096 @default.
• W2947394857 creator A5061017141 @default.
• W2947394857 creator A5064489084 @default.
• W2947394857 creator A5074371798 @default.
• W2947394857 creator A5076425371 @default.
• W2947394857 creator A5079523968 @default.
• W2947394857 creator A5090617575 @default.
• W2947394857 date "2019-04-30" @default.
• W2947394857 modified "2023-10-16" @default.
• W2947394857 title "Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma" @default.
• W2947394857 cites W1586421535 @default.
• W2947394857 cites W1840097866 @default.
• W2947394857 cites W1892405924 @default.
• W2947394857 cites W1928084746 @default.
• W2947394857 cites W1964991674 @default.
• W2947394857 cites W1966215698 @default.
• W2947394857 cites W1967863345 @default.
• W2947394857 cites W1971837077 @default.
• W2947394857 cites W1978612707 @default.
• W2947394857 cites W1978756427 @default.
• W2947394857 cites W1994193851 @default.
• W2947394857 cites W1996229105 @default.
• W2947394857 cites W2024884692 @default.
• W2947394857 cites W2028319026 @default.
• W2947394857 cites W2057378223 @default.
• W2947394857 cites W2070567343 @default.
• W2947394857 cites W2096137222 @default.
• W2947394857 cites W2159026435 @default.
• W2947394857 cites W2168742889 @default.
• W2947394857 cites W2176045506 @default.
• W2947394857 cites W2183204345 @default.
• W2947394857 cites W2184717004 @default.
• W2947394857 cites W2186902482 @default.
• W2947394857 cites W2214253982 @default.
• W2947394857 cites W2236150109 @default.
• W2947394857 cites W2277004004 @default.
• W2947394857 cites W2286222994 @default.
• W2947394857 cites W2321700333 @default.
• W2947394857 cites W2322546964 @default.
• W2947394857 cites W2333627087 @default.
• W2947394857 cites W2336895124 @default.
• W2947394857 cites W2528789218 @default.
• W2947394857 cites W2582878252 @default.
• W2947394857 cites W2661307008 @default.
• W2947394857 cites W2884494817 @default.
• W2947394857 cites W4210955410 @default.
• W2947394857 doi "https://doi.org/10.1186/s12885-019-5570-z" @default.
• W2947394857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6492437" @default.
• W2947394857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31039750" @default.
• W2947394857 hasPublicationYear "2019" @default.
• W2947394857 type Work @default.
• W2947394857 sameAs 2947394857 @default.
• W2947394857 citedByCount "12" @default.
• W2947394857 countsByYear W29473948572019 @default.
• W2947394857 countsByYear W29473948572020 @default.
• W2947394857 countsByYear W29473948572021 @default.
• W2947394857 countsByYear W29473948572022 @default.
• W2947394857 countsByYear W29473948572023 @default.
• W2947394857 crossrefType "journal-article" @default.
• W2947394857 hasAuthorship W2947394857A5002366018 @default.
• W2947394857 hasAuthorship W2947394857A5018694636 @default.
• W2947394857 hasAuthorship W2947394857A5023597320 @default.
• W2947394857 hasAuthorship W2947394857A5031254409 @default.
• W2947394857 hasAuthorship W2947394857A5036608985 @default.
• W2947394857 hasAuthorship W2947394857A5059500096 @default.
• W2947394857 hasAuthorship W2947394857A5061017141 @default.
• W2947394857 hasAuthorship W2947394857A5064489084 @default.
• W2947394857 hasAuthorship W2947394857A5074371798 @default.
• W2947394857 hasAuthorship W2947394857A5076425371 @default.
• W2947394857 hasAuthorship W2947394857A5079523968 @default.
• W2947394857 hasAuthorship W2947394857A5090617575 @default.
• W2947394857 hasBestOaLocation W29473948571 @default.
• W2947394857 hasConcept C126322002 @default.
• W2947394857 hasConcept C126838900 @default.
• W2947394857 hasConcept C12868164 @default.
• W2947394857 hasConcept C143998085 @default.
• W2947394857 hasConcept C178596483 @default.
• W2947394857 hasConcept C197934379 @default.
• W2947394857 hasConcept C2777793932 @default.
• W2947394857 hasConcept C2778019345 @default.
• W2947394857 hasConcept C2778695046 @default.
• W2947394857 hasConcept C2780140570 @default.
• W2947394857 hasConcept C2780192575 @default.
• W2947394857 hasConcept C50382708 @default.
• W2947394857 hasConcept C71924100 @default.
• W2947394857 hasConcept C90924648 @default.
• W2947394857 hasConceptScore W2947394857C126322002 @default.
• W2947394857 hasConceptScore W2947394857C126838900 @default.
• W2947394857 hasConceptScore W2947394857C12868164 @default.
• W2947394857 hasConceptScore W2947394857C143998085 @default.
• W2947394857 hasConceptScore W2947394857C178596483 @default.
• W2947394857 hasConceptScore W2947394857C197934379 @default.
• W2947394857 hasConceptScore W2947394857C2777793932 @default.

• next